<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70484">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889641</url>
  </required_header>
  <id_info>
    <org_study_id>5504</org_study_id>
    <nct_id>NCT01889641</nct_id>
  </id_info>
  <brief_title>IL-26 and Systemic Lupus Erythematosus</brief_title>
  <official_title>Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <authority>France : Agence national sécurité du médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy,
      underscoring the need to better dissection of the pathogenic mechanisms. Concordant with
      preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could
      be a marker of the disease activity and then a potential therapeutic target. In the present
      study, serum IL 26 level in lupus patients and control will be measured.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Assess serum IL-26 as a biological marker of SLE compared with sera from control subjects</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling</condition>
  <arm_group>
    <arm_group_label>Patients with lupus</arm_group_label>
    <description>Patients with lupus (four levels of activity disease)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <description>Subjects controls</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patient and healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnostic of Lupus according to ACR criteria ( four criteria are necessary)

          -  age &gt; 18 years old

        Exclusion Criteria:

          -  treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas Rhin</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Audrey Gorse, MD</last_name>
      <email>audrey.gorse@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Audrey Gorse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Mutter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
